Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells

Lung Cancer

Volumn 75, Issue 1, 2012, Pages 30-37

  Han, Shu Yan ^a   Zhao, Ming Bo ^b   Zhuang, Gui Bao ^a   Li, Ping Ping ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Gefitinib resistance; K ras mutations; Marsdenia tenacissima extract; NSCLC; T790M

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MARSDENIA TENACISSIMA EXTRACT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; XIAN AI PING;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CONDURANGO; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MARSDENIA TENACISSIMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENES, RAS; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MARSDENIA; MUTATION; PHOSPHORYLATION; PLANT EXTRACTS; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 83555173427     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.06.001     Document Type: Article

References (55)

1. Laskin J.J., Sandler A.B. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004, 30:1-17.
2. Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005, 315:971-979.
3. Drevs J., Medinger M., Schmidt-Gersbach C., Weber R., Unger C. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr Drug Targets 2003, 4:113-121.
4. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33:369-385.
5. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
6. Lee Y., Kim H., Han J., Yun T., Lee G., Kim H., et al. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. J Thorac Oncol 2010, 5:361-368.
7. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
8. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
9. Han S.W., Kim T.Y., Jeon Y.K., Hwang P.G., Im S.A., Lee K.H., et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006, 12:2538-2544.
10. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
11. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
12. Uramoto H., Sugio K., Oyama T., Sugaya M., Hanagiri T., Yasumoto K. Resistance to gefitinib. Int J Clin Oncol 2006, 11:487-491.
13. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 2007, 67:7807-7814.
14. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102:7665-7670.
15. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
16. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
17. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
18. Suda K., Murakami I., Katayama T., Tomizawa K., Osada H., Sekido Y., et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010, 16:5489-5498.
19. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
20. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13:2890-2896.
21. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
22. Okabe T., Okamoto I., Tsukioka S., Uchida J., Hatashita E., Yamada Y., et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009, 15:907-913.
23. Shimamura T., Li D., Ji H., Haringsma H.J., Liniker E., Borgman C.L., et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008, 68:5827-5838.
24. Sadava D., Still D.W., Mudry R.R., Kane S.E. Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett 2009, 277:182-189.
25. Huang M., Jin J., Sun H., Liu G. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus schizandrae. Cancer Chemother Pharmacol 2008, 62:1015-1026.
26. Ruan W.J., Lai M.D., Zhou J.G. Anticancer effects of Chinese herbal medicine, science or myth?. J Zhejiang Univ Sci B 2006, 7:1006-1014.
27. Xueyuan J.X. Zhongyao Dacidian 1977, Shanghai Science and Technology Press, Shanghai.
28. Zhang H., Tan A.M., Zhang A.Y., Chen R., Yang S.B., Huang X. Five new C21 steroidal glycosides from the stems of Marsdenia tenacissima. Steroids 2010, 75:176-183.
29. Luo S.Q., Lin L.Z., Geoffrey A.C., Xue L., Michael E.J. Polyoxypregnanes from Marsdenia tenacissima. Phytochemistry 1993, 34:1615-1620.
30. Hu Y.J., Shen X.L., Lu H.L., Zhang Y.H., Huang X.A., Fu L.C., et al. Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance in HepG2/Dox cells. J Nat Prod 2008, 71:1049-1051.
31. Wang W.Y., Zhou Y., Zhang X.J., Gao T.H., Luo Z.F., Liu M.Y. A random study of xiao-ai-ping injection combined with chemotherapy on the treatment of advanced non-small cell lung cancer. Chin Clin Oncol 2009, 14:936-938.
32. Wang K., Guo Z.X. Xiaoaiping injection combining with NP regiment in the treatment of 56 patients with advanced lung cancer. J Basic Clin Oncol 2009, 22:47-48.
33. Huang Z.Q., Tan H., Wang C.Y., Zhang H.Z., Liu D., Zhou C.Z., et al. Clinical research of combined xiaoaiping injection with chemotherapy on advanced non-small cell lung cancer. Chin Clin Oncol 2007, 12:97-99.
34. Janmaat M.L., Rodriguez J.A., Gallegos-Ruiz M., Kruyt F.A.E., Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006, 118:209-214.
35. Shimoyama T., Koizumi F., Fukumoto H., Kiura K., Tanimoto M., Saijo N., et al. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer 2006, 53:13-21.
36. Chou T.C., Motzer R.J., Tong Y., Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86:1517-1524.
37. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007, 67:2081-2088.
38. Engelman J.A., Jänne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005, 102:3788-3793.
39. Kokubo Y., Gemma A., Noro R., Seike M., Kataoka K., Matsuda K., et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005, 92:1711-1719.
40. Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29:2346-2356.
41. Yamada T., Matsumoto K., Wang W., Li Q., Nishioka Y., Sekido Y., et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010, 16:174-183.
42. Chen T.S., Wang X.P., Wang Z.P., Wang L.X., Wang H.Y., Xing D. Fluorescence emission analysis of caspase-3 activation induced by xiao-ai-ping (XAP) inside living human lung adenocarcinoma cells. Spectrosc Spec Anal 2008, 28:1327-1331.
43. Zucali P.A., Ruiz M.G., Giovannetti E., Destro A., Varella-Garcia M., Floor K., et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008, 19:1605-1612.
44. Miller K.A., Yeager N., Baker K., Liao X.H., Refetoff S., Cristofano A.D. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 2009, 69:3689-3694.
45. Tang Z., Du R., Jiang S., Wu C., Barkauskas D.S., Richey J., et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008, 99:911-922.
46. Richardson C., Richardson D., Swinson D., Swain W., Cox G., O'Byrne K. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 2005, 48:47-57.
47. Milligan S.A., Burke P., Coleman D.T., Bigelow R.L., Steffan J.J., Carroll J.L., et al. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 2009, 15:4885-4894.
48. Monica S.L., Galetti M., Alfieri R.R., Cavazzoni A., Ardizzoni A., Tiseo M., et al. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 2009, 78:460-468.
49. Filvaroff E, Merchant M, Yauch RL, inventors; Genentech, Inc. (South San Francisco, CA, US), assignee. Combination therapy with c-met and EGFR antagonists. United States; 2009.
50. 21 steroids from Marsdenia tenacissima. Chin Chem Lett 2005, 16:487-490.
51. Deng J., Liao Z., Chen D. Three new polyoxypregnane glycosides from Marsdenia tenacissima. Hel Chim Acta 2005, 88:2675-2682.
52. Wang X.L., Li Q.F., Yu K.B., Peng S.L., Yan Z., Sheng D.L. Four new pregnane glycosides from the stems of Marsdenia tenacissima. Hel Chim Acta 2006, 89:2738-2744.
53. 21 steroidal glycosides from Marsdenia tenacissima. Acta Bot Yunnanica 1999, 21:369-377.
54. Miyakawa S., Yamaura K., Hayashi K., Kaneko K., Mitsuhashi H. Five glycosides from the chinese drug 'tong-guang-san': the stems of marsdenia tenacissima. Phytochemistry 1986, 25:2861-2865.
55. Deng J., Liao Z., Chen D. Marsdenosides A-H, polyoxypregnane glycosides from Marsdenia tenacissima. Phytochemistry 2005, 66:1040-1051.